Anthropic (NASDAQ: ANT) gave back its first-day IPO gains within two sessions, falling from an intraday high of $115.10 on Nov. 19 to $83.15 the following day, close to its $83 offering price. Investors are weighing the completed underwriters’ option exercise, a potential supply of shares when lockups expire, and expected passive demand ahead of the company’s planned Nasdaq 100 inclusion on Dec. 21.
ANT opened at $111.50 on its first trading day, reached $115.10 and closed at $97.17, up about 17%. On Nov. 20, it opened at $89.86 before dropping to $83.15. The pullback came as the S&P 500 and Dow Jones Industrial Average entered correction territory and the Nasdaq Composite turned negative for the year, putting the newly listed AI company under pressure from both sector and broader market weakness.
Underwriters have exercised the full greenshoe
Anthropic’s base offering comprised 980 million shares. The underwriting agreement allowed the banks to buy an additional 147 million shares, equal to 15% of the base deal. In a typical IPO, underwriters can create a short position by over-allotting shares. If the stock trades below the offer price, buying shares in the market to cover that position may provide support. If it trades above the offer price, the banks can instead exercise the greenshoe and buy additional shares from the company at the offer price.
Anthropic’s offering completion notice said the underwriters exercised the full 147 million-share option, bringing the total offering to 1.127 billion shares. At $83 per share, IPO proceeds were about $93.5 billion. Including a concurrent $26 billion private financing, the combined amount was about $119.5 billion.
The exercise means the underwriting group has covered its short position by purchasing the additional shares, removing any remaining obligation to buy shares to close that position. Market buying may still occur near $83, but the IPO price is better viewed as a psychological reference point than a level the underwriters are bound to defend. Rule 104 of the U.S. Securities and Exchange Commission’s Regulation M permits stabilizing activity under specified conditions; with the underwriters’ short position covered, the economic incentive for those particular purchases has changed.
Up to 303 million shares become eligible for sale on Dec. 15
IPO shares represent about 8.6% of Anthropic’s shares outstanding. Registration filings with the SEC also allow non-founder employees to sell up to 10% of their holdings from the first day of trading, or about 315 million shares. Together, roughly 1.44 billion shares—about 11% of the company—are currently tradable.
Trading volume exceeded 846 million shares on the first day, roughly 75% of the IPO share count. The turnover points to heavy activity at the start of trading, though volume alone does not show how those investors will behave next.
Further lockups expire in stages. Up to 303 million shares become eligible for sale on Dec. 15, another 303 million on Jan. 5, 2027, and as many as 353 million shares on each of Jan. 19 and Feb. 2. At $83 per share, the Dec. 15 tranche has a notional value of about $25.1 billion. Eligibility to sell does not mean holders will sell, but it adds a potential source of supply for investors to monitor.
That potential supply is substantial relative to projected index demand. Bloomberg Intelligence estimates that a fast-track Nasdaq 100 inclusion could prompt about $4.6 billion in purchases by index-tracking funds, while broader estimates put first-month passive demand at roughly $19 billion. Depending on the estimates used, the shares becoming eligible for sale on Dec. 15 are at least as large as expected passive buying. The market impact will depend on holders’ willingness to sell and the market’s capacity to absorb the shares.
SpaceX, Meta and Uber offer different IPO comparisons
SpaceX, which went public in 2026 at $135 per share, closed its first day at $161 and reached an intraday high of $225.64 on June 16. It joined the Nasdaq 100 on July 7, but later closed below its IPO price for the first time on July 16 and fell to $104.83 on Aug. 3, about 22% below the offering price. The stock recovered after the first lockup expired, closing at $162.57 on Oct. 9.
Meta Platforms, then called Facebook, priced its 2012 IPO at $38 and closed its first day at $38.23. The shares fell below the offer price on the second trading day and slid to about $17.55 that September, more than 50% below the IPO price. Uber Technologies priced at $45 in 2019 and closed its first session at $41.57, below the offer price from day one.
These examples show that trading below an IPO price does not, by itself, determine a company’s long-term business performance, while also illustrating how steep post-listing declines can be. SpaceX’s continued slide after its Nasdaq 100 inclusion is a reminder that index buying does not necessarily prevent a short-term correction; some of that demand may also be priced in before inclusion takes effect.
Revenue surges as operating profit turns to a loss
Anthropic’s amended S-1 filing reported third-quarter 2026 revenue of $16.96 billion, up 1,127% year over year and 47% from the second quarter. Revenue over the past 12 months was about $35.3 billion. Profitability moved in the opposite direction: the company recorded $974 million in operating profit in the second quarter, then reported an operating loss of $567 million in the third.
Computing and infrastructure costs rose to 58% of revenue in the third quarter, up from 48% in the second. Anthropic said it had used some higher-priced short-term computing capacity and disclosed about $895 billion in computing and infrastructure commitments. The combination of rapid revenue growth, rising costs and a quarterly swing to an operating loss is central to how investors assess the company’s valuation.
At a share price of about $83 to $84, Anthropic’s market capitalization is roughly $1.1 trillion on a basic share count, or about 31 times trailing 12-month revenue. Annualizing third-quarter revenue to $67.8 billion and using a fully diluted valuation of about $1.5 trillion gives a price-to-sales multiple of roughly 22 times. On consensus expectations for about $128 billion in 2027 revenue, the fully diluted multiple is around 12 times. The latter two measures depend on projected growth; whether profitability improves remains a key variable.
Competition is another consideration. Michael Burry recently said Anthropic is seeking to take enterprise customers from Palantir Technologies. Expansion in the enterprise market supports the company’s growth case, while also raising expectations for continued growth and quarterly results.
Dates and price levels to watch over the next month
ANT options, along with Tradr’s 2x long ETF ANTT and 2x short ETF ANTZ, are expected to begin trading on Nov. 23. Options and leveraged products can add hedging activity and amplify moves in either direction, depending on positioning and subsequent trading. Nov. 30 is the ranking date for a fast-track Nasdaq 100 inclusion, when investors will be watching for confirmation and details of potential passive demand.
The Federal Reserve is scheduled to announce its rate decision on Dec. 9; markets at the time were pricing in a rate hike. Changes in interest rates can affect growth stocks whose valuations are sensitive to future cash flows. Around Dec. 14, the underwriters’ analyst quiet period is expected to end, allowing analysts at the underwriting banks to begin publishing research. Dec. 15 marks the first major lockup expiration, while Dec. 18–21 brings quarterly derivatives expirations and the expected Nasdaq 100 inclusion, set to take effect at the open on Dec. 21.
With only a short trading history, moving averages and the relative strength index have limited data to draw on. Reference levels include the first-day high of $115.10, first-day close of $97.17, first-day low of $92.72 and the $83 offer price. Based on the range from $83 to $115.10, Fibonacci retracement levels are about $102.84, $99.05 and $95.26. These levels reflect past trading, not a guarantee of future price action.
As of Nov. 20, investors were balancing rapid growth against a third-quarter operating loss, a fully exercised greenshoe and the prospect of concentrated share supply in mid-December alongside expected index demand. The $83 IPO price remains a closely watched reference, but the underwriters’ short position has been covered, and the offer price does not establish a formal support mechanism.